Evidence map›Paper›PMID 42412011›Full record

ArticleAngewandte Chemie (International ed. in English)2026

Harnessing the Reactivity of Sulfinate Salts With Cystine: An Umpolung Approach to Residue-Specific Peptide Modification.

Joshua M Hammond, Esteban Suárez-Picado, Lena von Sydow, Hanna Bruss, Laurent Knerr, Magnus Johansson, Anaïs Noisier, Lara R Malins

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Joshua M HammondResearch School of Chemistry, Australian National University, Canberra, Australia.
Esteban Suárez-PicadoResearch School of Chemistry, Australian National University, Canberra, Australia.
Lena von SydowMedicinal Chemistry Respiratory and Immunology (R&I), Discovery Sciences, BioPharmaceuticals R&D AstraZeneca, Gothenburg, Sweden.
Hanna BrussMedicinal Chemistry Cardiovascular, Renal and Metabolism (CVRM), Discovery Sciences, BioPharmaceuticals R&D AstraZeneca, Gothenburg, Sweden.
Laurent KnerrMedicinal Chemistry Cardiovascular, Renal and Metabolism (CVRM), Discovery Sciences, BioPharmaceuticals R&D AstraZeneca, Gothenburg, Sweden.
Magnus JohanssonMedicinal Chemistry Cardiovascular, Renal and Metabolism (CVRM), Discovery Sciences, BioPharmaceuticals R&D AstraZeneca, Gothenburg, Sweden.
Anaïs NoisierMedicinal Chemistry Cardiovascular, Renal and Metabolism (CVRM), Discovery Sciences, BioPharmaceuticals R&D AstraZeneca, Gothenburg, Sweden.
Lara R MalinsResearch School of Chemistry, Australian National University, Canberra, Australia.ORCID 0000-0002-7691-6432

Funding

Australian Research Council CE200100012Australian Research Council FT240100010Snow Medical SMRF2023-158
6 · The paper itself

Abstract

The first use of sulfinate salts for the late-stage modification of peptidic disulfide bonds is reported. While the majority of cysteine-based peptide modifications rely on the nucleophilicity of the side chain thiol functionality, umpolung approaches-exploiting instead the electrophilicity of the cystine disulfide-are underexplored. Using structurally diverse sulfinate salts, we have optimized a mild, photochemical strategy for the generation and coupling of carbon-centered radicals with both symmetrical and electronically-distinct, unsymmetrical cystine disulfides using high-throughput experimentation techniques. A library of modified peptides was accessible, as confirmed by qualitative and quantitative analytical data, providing valuable insights into the matched reactivity of specific radical/disulfide substrate pairings. The method was broadly compatible with a range of unprotected amino acids, including histidine, tryptophan, and tyrosine, and can be used for the functionalization of biologically relevant peptides, as exemplified by the selective, late-stage modification of a semaglutide analogue and the preparation of high-value macrocyclic peptides.

Indexed as

CystinePeptidesSulfinic AcidsDisulfidesSaltsCystineDisulfidesPeptidesSaltsSulfinic Acidscysteine modificationhigh‐throughput experimentationpeptide modificationsulfinatesumpolung

Identifiers

PMID42412011
PMCPMC13549023

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.